Showing 7061-7070 of 9134 results for "".
- Scary Findings About Common Dermatologic Features of Classic Movie Villainshttps://practicaldermatology.com/news/study-ids-scary-findings-about-common-dermatologic-features-of-classic-movie-villains/2458227/What makes a villain (besides malice)? Scars, warts, deep wrinkles and alopecia, according to a new study that sought to identify the common dermatologic features of classic movie villains including Dr. Hannibal Lecter (“The Silence of the Lambs,” 1991), Mr. Potter (“It&
- Apax Partners To Acquire Syneron for Close to $400 millionhttps://practicaldermatology.com/news/apax-partners-to-acquire-syneron-for-close-to-400-million/2458230/An affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million. The per share acquisition price repr
- Allergan and Paratek Pharmaceuticals' Acne Drug Performs Well in Phase 3 Trialshttps://practicaldermatology.com/news/allergan-and-paratek-pharmaceuticals-acne-drug-performs-well-in-phase-3-trials/2458234/Allergan and Paratek Pharmaceuticals, Inc.’s investigational acne drug performed well in two Phase 3 studies, the companies report. Sarecycline, a once-daily, oral, narrow spectrum tetracycline-derived anti
- Study: Severe Psoriasis More Common in Menhttps://practicaldermatology.com/news/severe-psoriasis-more-common-in-men/2458235/Severe psoriasis predominantly affects men, according to a new study in the American Journal of Clinical Dermatology. In the study of 5,438 Swedish psoriasis patients, women had significantly (p<0.
- 5α-Reductase Inhibitors Not Associated with Increased Suicide Risk in Older Menhttps://practicaldermatology.com/news/5-reductase-inhibitors-not-associated-with-increased-suicide-risk-in-older-men/2458240/Using 5α- reductase inhibitors was not associated with increased suicide risk in a group of older men, according to new research in JAMA Internal Medicine. Risks f
- FDA Approved Juvéderm Vollure XC for Correction of Facial Wrinkles and Foldshttps://practicaldermatology.com/news/fda-approved-juvderm-vollure-xc-for-correction-of-facial-wrinkles-and-folds/2458241/The FDA has approved Allergan plc's Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US pivotal clinical trial, a majority (59 percent) of subjects saw improvement in moderate to severe na
- Heliocare Spotlights Improved Formulation: Vegan, Gluten-free, and Dye-freehttps://practicaldermatology.com/news/heliocare-spotlights-improved-formulation-vegan-gluten-free-and-dye-free/2458243/Heliocare Daily Use Antioxidant Formula, a clinically proven, natural dietary supplement with antioxidant effects on the skin, has been updated to be vegan, gluten-free, and free of artificial dyes. The once-daily capsules from Ferndale Healthcare, have been recommended by dermatologists fo
- AAD Throws Some Shade At 26 Schools With 2017 Shade Structure Grantshttps://practicaldermatology.com/news/aad-throws-some-shade-at-26-schools-with-2017-shade-structure-grants/2458245/The American Academy of Dermatology (AAD) awarded shade structure grants to 26 schools and non-profit organizations across the country. Since its launch in 2000, the AAD’s Shade Structure Grant Program has awarded 350 shade structure grants, which pr
- Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc.https://practicaldermatology.com/news/pershing-square-capital-management-lp-announces-sale-of-its-investment-in-valeant-pharmaceuticals-international-inc/2458249/Pershing Square Capital Management, L.P. (“Pershing Square”) announced today that it has sold its investment in Valeant Pharmaceuticals International, Inc. (“Valeant”) (ticker: NYSE: VRX). Pershing Square CEO Bill Ackman and Vice Chairman Steve Fraidin will remain on the V
- Survey Findings: Submental Region Major Pain Point for Patientshttps://practicaldermatology.com/news/survey-findings-submental-region-major-pain-point-for-patients/2458247/Close to 50 percent of individuals are bothered by the appearance of the area under their chin, and many alter their behavior as a result, according to a new survey commissioned by